Evaluation of In-vitro Cytotoxicity Activity of Costus igneus (Insulin Plant) and the Potential Role of its Phytochemical Constituents in Hepatocellular Carcinoma | Chapter 7 | Advanced Concepts in Pharmaceutical Research Vol. 3

 Costus igneus and allure secondary metabolites have happened widely evaluated and used to treat subjects with diabetes with metabolic condition. Recent evidence submitted that non-alcoholic fatty liver affliction (NAFLD) and diabetes associated metabolic condition were the important risk factors for hepatocellular abnormal growth in animate being (HCC). So, herbals with insulin sensitizing characteristics have a promising duty in the control of metabolic syndrome and tumor. This study was conducted to evaluate the artificial anticancer activity of the ethanolic extract of Costus igneus leaves against hepatocellular abnormal growth in animate being (HepG2) cells. Artificial cytotoxicity activity (MTT assay) of the plant extract leaves was acted with eight different concentrations (1000 to7.8µg/ml) and the allotment of viability was premeditated from the graph. The aggregation required for a 50% being inhibition (IC 50) was calculated as 62.5µg/ml. Still, 74.57% and 22.65% of cell animation were produced apiece concentration of 7.8µg/ml and 1000µg/ml individually. These results observed the cytotoxic activity of ethanolic extract of Costus igneus leaves and confirmed the potential role of Costus igneus phytochemical possessions against hepatocellular carcinoma.

Author(s) Details:

Glory Josephine I.,
Department of Pharmacology, Sree Balaji Medical College & Hospital, Bharath Institute of Higher Education and Research (BIHER), Chennai 600044, India.

Please see the link here: https://stm.bookpi.org/ACPR-V3/article/view/12700

Beneficial Effects of Hydrogen Water on Subjects with NAFLD | Chapter 8 | Research Developments in Medicine and Medical Science Vol. 4

 Non-alcoholic greasy liver disease (NAFLD) is a liver disorder that influences approximately a quarter of the all-encompassing population. It is caused by an exuberance of oxidative stress, inflammation, and irregular cellular indicating, which can influence liver dysfunction and eventually, carcinoma. Molecular hydrogen has existed identified for allure specific antioxidant characteristics and ability to decrease inflammation and regulate natural activity. In a randomized, double-blind, fake pill-controlled trial unending eight weeks, hydrogen-rich water (HRW) was given to 30 matters with NAFLD. We noticed approving trends (p > 0.05) in abated weight (about 1 kg) and party mass index in the HRW group. HRW was well-indulged, with no significant changes in liver enzymes and an slant towards improved lipid sketch and lower lactate dehydrogenase levels. HRW went to decrease nuclear determinant kappa B, heat shock protein 70, and matrix metalloproteinase-9 levels non-significantly. Curiously, skilled was a slight but non-significant increase in the levels of 8-hydroxy-2’-deoxyguanosine and malondialdehyde in the HRW group. This gentle increase may desire hormetic effects of microscopic hydrogen. Further, longer-term studies focused on barring, maintaining, or discussing NAFLD and early stages of NASH are necessary.

Author(s) Details:

Branislav Kura

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Maria Szantova

3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovak Republic.

 

Tyler W. LeBaron

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic, Molecular Hydrogen Institute, 847 21 Enoch, UT, USA and Department of Kinesiology and Outdoor Recreation, Southern Utah University, 847 21Cedar City, UT, USA.

 

Viliam Mojto

3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovak Republic.

 

Miroslav Barancik

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Barbara Szeiffova Bacova

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Barbora Kalocayova

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Matus Sykora

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Ludmila Okruhlicova

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Narcisa Tribulova

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

 

Anna Gvozdjakova

Pharmacobiochemical Laboratory of 3rd Medical Department, Medical Faculty, Comenius University Bratislava, 811 08 Bratislava, Slovak Republic.

 

Zuzana Sumbalova

Pharmacobiochemical Laboratory of 3rd Medical Department, Medical Faculty, Comenius University Bratislava, 811 08 Bratislava, Slovak Republic.

 

Jarmila Kucharska

Pharmacobiochemical Laboratory of 3rd Medical Department, Medical Faculty, Comenius University Bratislava, 811 08 Bratislava, Slovak Republic.

 

Xenia Faktorova

Internal Clinic of Slovak Medical University, Hospital of St. Michael, 811 08 Bratislava, Slovak Republic.

 

Martina Jakabovicova

3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovak Republic. 

Zuzana Durkovicová

3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovak Republic. 

Jan Macutek

Mathematical Institute, Slovak Academy of Sciences 814 73 Bratislava, Slovak Republic and Department of Mathematics, Faculty of Natural Sciences, Constantine the Philosopher University in Nitra, 949 01 Nitra, Slovak Republic.

 

Michaela Koscová

Mathematical Institute, Slovak Academy of Sciences 814 73 Bratislava, Slovak Republic.

 

Jan Slezak

Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 841 04 Bratislava, Slovak Republic.

Please see the link here: https://stm.bookpi.org/RDMMS-V4/article/view/9837

Low Carb High Protein Diets to Treat Insulin Resistance in Patients with Obesity and/or Type 2 Diabetes Mellitus| Chapter 7 | Current Overview on Disease and Health Vol. 7

Low carbohydrate, high protein diets have been prescribed since 1797 and are taken seriously by many researchers and health professionals, though the diet is still met with skepticism in mainstream dietetics and medicine. Insulin resistance (IR) is caused by a series of physiological events that begin with hyperfagia and progress to a positive energy balance and weight gain. Because of their high insulin levels, patients with IR gain weight easily and have difficulty losing weight on diets with a normal carbohydrate content. A diet for patients with IR must therefore tackle this problem to make weight loss possible. Recently, developments in the management of type 2 diabetes mellitus incline towards lowering of carbohydrate intakes to put T2DM in remission, making it even more important to look carefully at the evidence, because patients may benefit from it in a direct way. This review discusses the evidence on the diet's short and long-term effects, effects on comorbidities, and differences from the Mediterranean diet. A search was carried out in Pubmed for articles of obesity management, IR, low carb/high protein diets and weight loss combined with comorbidities, several nutrients and the Mediterranean diet between 1995 and July 2017. In weight loss management, the outcomes were compared to patient observations from dietary practice.

Waist circumference measurement makes diagnosis simple. The diet should be low in carbohydrates and rich in protein without inducing ketosis; each person's needs for energy and macronutrients should be considered. Focusing on unsaturated fats, fat is neither too high nor excessively low. Magnesium, iodine, and vitamin D intake must be at recommended levels. Alcohol consumption is not included in the diet's initial phase. Exercise is a crucial component of treatment because it builds endurance and resistance. Patients taking type 2 diabetes medication need to carefully monitor their food and glucose levels. Low carbohydrate/high protein diets should be considered as a serious treatment option for all obese patients with and without comorbidities. They should be administered by specialized dietitians as part of a multidisciplinary team. Low carbohydrate/high protein diets should be considered as a serious treatment option for all obese patients with and without comorbidities. They should be administered by specialised dietitians working in a multi-disciplinary team.

Author(s) Details:

Elisabeth Govers,
Dutch Knowledge Centre for Dietitians on Obesity, Amsterdam, The Netherlands and European Specialist Dietetic Network on Obesity, European Federation of the Associations of Dietitians (EFAD), Naarden, The Netherlands and Nutrition Working Group, European Association for the Study of Obesity (EASO), Teddington, UK.

Please see the link here: https://stm.bookpi.org/CODH-V7/article/view/9081